If you or someone close to you has recently had a biopsy, you may have come across the term IHC test on a pathology report and wondered what it actually means. Immunohistochemistry, or IHC, is one of the most widely used tools in modern pathology, and it plays a central role in how cancers and other diseases are diagnosed and classified. This guide walks through what an IHC test is, how it works, what the markers mean, and how to read a result, in plain terms.
What Is an IHC Test?
An IHC test is a laboratory procedure that uses antibodies to detect specific proteins in a tissue sample. Instead of simply looking at how cells appear under a microscope, which is what conventional histopathology does, an IHC test goes a step further and identifies what those cells are actually producing at a molecular level. A thin slice of tissue, usually taken from a biopsy or surgical sample, is treated with antibodies designed to bind to a particular protein. If that protein is present, the antibody attaches to it, and a staining reaction makes it visible under a microscope. This allows a pathologist to see not just the shape and structure of cells, but also specific markers that reveal what type of cells they are and how they are behaving.
What Does an IHC Test Detect?
An IHC test detects specific proteins, often called antigens or biomarkers, expressed on or inside cells. These proteins can indicate the type of tissue a cell originated from, whether a cell is dividing rapidly, whether it carries hormone receptors, or whether it belongs to a particular category of immune or cancer cell. Because different cell types produce different combinations of proteins, IHC testing gives pathologists a way to fingerprint a tissue sample well beyond what basic morphology can show. It can detect the presence, absence, or level of expression of a target protein, which becomes the basis for classifying and diagnosing what is happening in that tissue.
Why Is an IHC Test Performed?
An IHC test is most commonly performed to help confirm or refine a diagnosis after an initial tissue examination raises a question that standard staining cannot fully answer. This includes determining whether a tumor is benign or malignant, identifying the specific type or subtype of cancer, tracing a metastatic tumor back to its original site when that isn't obvious, and distinguishing between conditions that look similar under a microscope but behave very differently. It is also used to guide treatment decisions, since certain therapies only work on cancers that express particular markers, and to assess prognosis, since some markers are linked to how aggressively a disease is likely to progress.
How Does an IHC Test Work?
The process begins with a tissue sample, typically fixed in formalin and embedded in paraffin wax to preserve its structure. This tissue is cut into extremely thin sections and mounted on slides. The sections then go through antigen retrieval, a step that reverses some of the changes caused by fixation so that the target protein becomes accessible to antibodies again. A primary antibody specific to the protein of interest is applied to the tissue, and if that protein is present, the antibody binds to it. A detection system, often involving a secondary antibody linked to an enzyme, is then applied, followed by a chromogen that produces a visible color wherever the antibody has bound. The slide is counterstained so the surrounding tissue structure remains visible, and a pathologist examines it under a microscope to interpret the pattern, location, and intensity of staining.
What Are IHC Markers?
IHC markers are the specific antibodies used in a test, each one targeting a particular protein associated with a certain cell type, function, or disease process. A marker is essentially a biological flag. When an antibody for that marker binds and produces staining, it confirms that the corresponding protein is present in the tissue. Pathologists rarely rely on a single marker. Instead, they typically use a panel of several markers together, since combining results gives a much clearer and more reliable picture than any one marker could provide alone.
Common IHC Markers and What They Help Identify
Different markers serve different diagnostic purposes. Cytokeratins help confirm whether a tumor originated from epithelial tissue. Estrogen and progesterone receptor markers indicate whether a breast cancer is hormone driven, which affects treatment choice. HER2 identifies tumors that overexpress a growth-related protein and may respond to targeted therapy. Ki-67 measures how rapidly cells are dividing, giving insight into how aggressive a tumor may be. CD markers, such as CD20 or CD3, help classify different types of lymphoma by identifying which immune cells are involved. TTF-1 supports identifying whether a tumor originated in the lung or thyroid. Each of these markers answers a narrow, specific question, and together they build toward a complete diagnostic picture.
IHC Test for Cancer Diagnosis
Cancer diagnosis is one of the most common reasons an IHC test is ordered. Many cancers look similar to each other, or even similar to non-cancerous conditions, when viewed through standard tissue staining alone. IHC testing allows pathologists to confirm the specific type of cancer present, determine its subtype where that distinction affects treatment, and identify the primary source of a tumor that has spread to another part of the body. This last use is particularly important in cases of metastatic cancer of unknown origin, where finding the original tumor site can significantly change the treatment approach.
What Do IHC Test Results Mean?
IHC test results describe whether a particular marker was detected in the tissue, and often how strongly. Results are usually reported as positive or negative, and for some markers, as a percentage of stained cells or an intensity score. These results are never read in isolation. A pathologist interprets them alongside the standard tissue examination and the patient's overall clinical picture, since the same marker can mean different things depending on the type of tissue and the clinical context it appears in.
What Does IHC Positive Mean?
A positive IHC result means the antibody detected the target protein in the tissue sample, meaning that protein is present or overexpressed in the cells being examined. What this means clinically depends entirely on which marker was tested and what type of tissue was involved. A positive result for a hormone receptor in breast tissue, for example, points toward a specific treatment pathway, while a positive result for a different marker in a different context may support a diagnosis or help classify a tumor subtype. A positive result on its own is not something to interpret without the full report, and any questions about what a specific positive result means for an individual case are best directed to the treating physician.
What Does IHC Negative Mean?
A negative IHC result means the antibody did not detect a meaningful level of the target protein in the tissue. This does not automatically rule out disease, and it does not mean a test failed. Many diagnostic panels include markers that are expected to be negative, with that absence itself providing useful information by helping rule out certain conditions or cell types. A negative result is interpreted the same way a positive one is, in the context of the other markers tested and the overall clinical picture, rather than as a standalone answer.
How Long Does an IHC Test Take?
Most IHC tests take between one and three days from the time the tissue is processed to when results are ready, though this can vary. Standard processing, staining, and pathologist review typically fall within this window, but the timeline can extend if multiple markers need to be tested, if additional stains are requested after an initial review, or if a sample requires special handling. Labs with efficient workflows and well-validated protocols tend to deliver more predictable turnaround times, which matters for patients waiting on results that will guide treatment decisions.
How Is an IHC Test Different From Histopathology?
Histopathology is the broader examination of tissue structure, typically using a basic stain such as hematoxylin and eosin, which shows cell shape, tissue architecture, and general patterns of abnormality. It is usually the first step in evaluating a biopsy. An IHC test is a more targeted, molecular-level extension of that examination, used when the standard tissue view raises a question that needs a more specific answer. Rather than replacing histopathology, IHC testing builds on it, most often ordered as a follow-up step to confirm a suspected diagnosis, classify a tumor more precisely, or identify a marker relevant to treatment.
What Factors Affect IHC Test Quality?
The reliability of an IHC test depends on several factors working correctly together. Proper tissue fixation and processing preserve the protein structures the test depends on, and inconsistent fixation is one of the most common sources of unreliable results. Antigen retrieval needs to be matched correctly to the tissue and target protein. The antibody itself needs to be specific and consistent from one lot to the next, since a weak or cross-reactive antibody can produce misleading staining regardless of how well the rest of the protocol is followed. Laboratory expertise and the use of proper positive and negative control tissue alongside each test batch also play a significant role in ensuring results can be trusted.
Frequently Asked Questions About IHC Tests
Is an IHC test painful? The test itself is performed on tissue that has already been removed during a biopsy or surgery, so it does not involve any additional procedure or discomfort for the patient.
Is an IHC test used only for cancer diagnosis? No. While cancer diagnosis is its most common use, IHC testing is also used to help diagnose infections, autoimmune conditions, and other diseases where identifying specific proteins in tissue provides diagnostic value.
How accurate is an IHC test? When performed with a well-validated antibody, proper controls, and correct protocol, IHC testing is highly reliable. Accuracy depends heavily on antibody quality, laboratory technique, and correct interpretation, which is why results are always read by a trained pathologist rather than generated automatically.
Can an IHC test give a false result? Like any laboratory test, IHC testing can occasionally produce a false positive or false negative, usually linked to tissue fixation issues, antibody performance, or technical variation. This is why panels of multiple markers, rather than a single marker, are typically used for important diagnostic decisions.
Do all biopsies require an IHC test? No. Many biopsies are fully diagnosed through standard histopathology alone. An IHC test is ordered specifically when the initial tissue examination leaves a diagnostic question that a targeted marker can help answer.
If you have received a pathology report that includes IHC results and have questions about what they mean for your specific situation, the right next step is always a conversation with the physician who ordered the test, since they can interpret the findings in the context of your full clinical picture.
